NCT05011396Phase 3Terminated

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

Study sponsor: VistaGen Therapeutics, Inc. · VTGN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-08-16Actual
Enrollment · participants228Actual
Source updated2025-11-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Actual enrollment increased by 87 participants

Before: 141 participants (actual). After: 228 participants (actual).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview